Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 233.67M | 182.95M | 129.62M | 83.37M | 42.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.67M | 182.95M | 129.62M | 83.37M | 42.56M |
| Cost of Revenue | 72.11M | 66.21M | 58.93M | 56.05M | 53.27M |
| Gross Profit | 161.56M | 116.74M | 70.69M | 27.33M | -10.71M |
| SG&A Expenses | 270.73M | 237.31M | 211.29M | 183.70M | 145.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 342.84M | 303.52M | 270.22M | 239.75M | 198.45M |
| Operating Income | -109.17M | -120.57M | -140.60M | -156.37M | -155.89M |
| Income Before Tax | -104.94M | -115.55M | -134.34M | -150.07M | -148.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.94 | -115.55 | -134.34 | -150.07 | -148.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.94M | -115.55M | -134.34M | -150.07M | -148.21M |
| EBIT | -109.17M | -120.57M | -140.60M | -156.37M | -155.89M |
| EBITDA | -107.75M | -119.34M | -139.46M | -155.27M | -154.85M |
| EPS Basic | -2.73 | -3.10 | -3.81 | -4.48 | -4.77 |
| Normalized Basic EPS | -1.65 | -1.87 | -2.31 | -2.72 | -2.94 |
| EPS Diluted | -2.73 | -3.10 | -3.81 | -4.48 | -4.77 |
| Normalized Diluted EPS | -1.65 | -1.87 | -2.31 | -2.72 | -2.94 |
| Average Basic Shares Outstanding | 154.11M | 150.07M | 143.45M | 135.69M | 124.68M |
| Average Diluted Shares Outstanding | 154.11M | 150.07M | 143.45M | 135.69M | 124.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |